Keywords
diabetes mellitus, heart failure, chronic kidney disease, hepatic impairment, pharmacokinetics
How to Cite
Vlasenko, M., Baranova, A., & Poliak, R. (2023). Management of diabetes mellitus and heart failure in chronic kidney disease and hepatic impairment. The Practitioner, (4), 44-50. Retrieved from https://plr.com.ua/index.php/journal/article/view/775
Abstract
The article describes the management of diabetes mellitus and heart failure in chronic kidney disease and hepatic impairment of different severity. The authors highlight in detail the main pharmacokinetics of the drugs according to the guidelines of the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the State Register of Medicines of Ukraine, which allows the doctor to prescribe rational and personalised medical treatment, optimise the treatment regimen and minimise the side effects of therapy in comorbid patients.
References
1. Forouhi NG & Wareham NJ. Epidemiology of diabetes. Medicine. 2022.
2. McDonagh TA, Metra M, Adamo M, Gardne RS, Baumbach A, Böhm M & Kathrine Skibelund A. 2021 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of
the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal.
2021;42(36):3599-3726.
3. Siao WZ, Chen YH, Tsai CF, Lee CM & Jong GP. Diabetes Mellitus and Heart Failure. Journal of Personalized Medicine. 2022;12(10):1698.
4. Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K & Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Journal
of Gastroenterology. 2021;56(7):593-619.
5. Tsoris A & Marlar CA. Use of the Child Pugh score in liver disease. 2019.
6. Talal AH, Venuto CS & Younis I. Assessment of hepatic impairment and implications for pharmacokinetics of substance use treatment. Clinical
pharmacology in drug development. 2017;6(2):206-212.
7. Xanthopoulos A, Starling RC, Kitai T & Triposkiadis F. Heart failure and liver disease: cardiohepatic interactions. JACC: Heart Failure. 2019;7(2):87-97.
8. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL M, De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ, Levey AS, Riella MC, Shlipak
MG, Wang H, White CT & Winearls CG. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline
for the evaluation and management of chronic kidney disease. Kidney International Supplements. 2013;3(1):1-150. https://doi.org/10.1038/
kisup.2012.73
9. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM & Bakris G. Diabetes management in chronic kidney disease: a consensus report
by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-3090.
10. House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P & Weir MR. Heart failure in chronic kidney disease: conclusions from a Kidney
Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international. 2019;95(6):1304-1317.
11. Kosmalski M, Śliwińska A & Drzewoski J. Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus − The Chicken or the Egg Dilemma.
Biomedicines. 2023;11(4):1097.
12. Vetrano E, Rinaldi L, Mormone A, Giorgione C, Galiero R, Caturano A & Sasso FC. Non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and
non-viral hepatocarcinoma: Pathophysiological mechanisms and new therapeutic strategies. Biomedicines. 2023;11(2):468.
13. Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney and Dialysis. 2022;2(3):433-442.
2. McDonagh TA, Metra M, Adamo M, Gardne RS, Baumbach A, Böhm M & Kathrine Skibelund A. 2021 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of
the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal.
2021;42(36):3599-3726.
3. Siao WZ, Chen YH, Tsai CF, Lee CM & Jong GP. Diabetes Mellitus and Heart Failure. Journal of Personalized Medicine. 2022;12(10):1698.
4. Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K & Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Journal
of Gastroenterology. 2021;56(7):593-619.
5. Tsoris A & Marlar CA. Use of the Child Pugh score in liver disease. 2019.
6. Talal AH, Venuto CS & Younis I. Assessment of hepatic impairment and implications for pharmacokinetics of substance use treatment. Clinical
pharmacology in drug development. 2017;6(2):206-212.
7. Xanthopoulos A, Starling RC, Kitai T & Triposkiadis F. Heart failure and liver disease: cardiohepatic interactions. JACC: Heart Failure. 2019;7(2):87-97.
8. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL M, De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ, Levey AS, Riella MC, Shlipak
MG, Wang H, White CT & Winearls CG. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline
for the evaluation and management of chronic kidney disease. Kidney International Supplements. 2013;3(1):1-150. https://doi.org/10.1038/
kisup.2012.73
9. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM & Bakris G. Diabetes management in chronic kidney disease: a consensus report
by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-3090.
10. House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P & Weir MR. Heart failure in chronic kidney disease: conclusions from a Kidney
Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international. 2019;95(6):1304-1317.
11. Kosmalski M, Śliwińska A & Drzewoski J. Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus − The Chicken or the Egg Dilemma.
Biomedicines. 2023;11(4):1097.
12. Vetrano E, Rinaldi L, Mormone A, Giorgione C, Galiero R, Caturano A & Sasso FC. Non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and
non-viral hepatocarcinoma: Pathophysiological mechanisms and new therapeutic strategies. Biomedicines. 2023;11(2):468.
13. Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney and Dialysis. 2022;2(3):433-442.
Downloads
Download data is not yet available.